Drs. Kislovskiy and Jarlenski found that pharmacies were unlikely to carry PrEP or PEP, with event less carrying in rural compared to urban. Addressing pharmacy barriers to PrEP/PEP may enhance access to HIV prevention for those living at high risk of HIV.
https://www.sciencedirect.com/science/article/pii/S1544319124001043
The freedom to use one’s preferred contraceptive method—or no method—is fundamental to reproductive autonomy, which is a particularly salient issue for disabled people, who face substantial barriers to person-centered contraceptive care while also being subjected to interference in reproductive decision making.
Drs. Mendez, Jarlenski, Chang, and their team measured racial inequities in drug testing among pregnant people and found that clinicians were more likely to order urine drug testing for Black patients compared with their White counterparts.
Read more of their findings here: https://pubmed.ncbi.nlm.nih.gov/37769307/
Dr. Marian Jarlenski's recent study shows:
• There are racial/ethnic inequities in medication for opioid use disorder (MOUD) use during pregnancy.
• Less is known about racial/ethnic inequities in MOUD use postpartum.
• White women had longer duration of MOUD postpartum than Hispanic or Black women.
• Inequities differed by type of MOUD.
• Reducing inequities in MOUD use is critical to improving perinatal outcomes.
Drs. Jarlenski and Krans conducted a scoping review including seven studies that highlight the literature's limited understanding of why women in the first year postpartum are particularly vulnerable to opioid overdose. Recomendations within the literature include:
Dr. Marian Jarlenski's study looked at the duration of medication for opioid use disorder during pregnancy and postpartum by race and ethnicity in Medicaid and found that:
- There are racial/ethnic inequities in MOUD use during pregnancy.
- Less is known about racial/ethnic inequities in MOUD use postpartum.
- White women had longer duration of MOUD postpartum than Hispanic or Black women.
- Inequities differed by type of MOUD.
Drs. Gao, Krans, and Jarlenski found in their recent study that female parents are less likely to be diagnosed with a substance use disorder (SUD) or receive medication for an opioid use disorder (MOUD) than male parents. Removing policies that criminalize parental SUD and addressing childcare-related barriers may improve SUD identification and treatment.
Read more about their findings here: https://pubmed.ncbi.nlm.nih.gov/37214425/
Drs. Jarlenski, Brown-Podgorski, and Krans sought to understand associations between race, receiving urine toxicology testing, and positive test results among pregnant patients. Findings show that Black patients experience increased drug testing practices.
Read more about their findings here: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2803729
Drug overdose is a leading cause of pregnancy-associated mortality in the US. This seminar will address the proximal and systemic contributors to reproductive and pregnancy outcomes, drawing on examples from research using health services research and implementation science methods to study persons who use substances in pregnancy.
Congratulations to Dr. Marian Jarlenski for a successful PCORI grant focused on improving pregnancy-related health outcomes.
